Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

CorMedix (CRMD) EBIT: 2012-2025

Historic EBIT for CorMedix (CRMD) over the last 12 years, with Sep 2025 value amounting to $51.3 million.

  • CorMedix's EBIT rose 1661.93% to $51.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $104.0 million, marking a year-over-year increase of 327.17%. This contributed to the annual value of -$22.4 million for FY2024, which is 54.34% up from last year.
  • According to the latest figures from Q3 2025, CorMedix's EBIT is $51.3 million, which was up 162.73% from $19.5 million recorded in Q2 2025.
  • CorMedix's 5-year EBIT high stood at $51.3 million for Q3 2025, and its period low was -$16.7 million during Q1 2024.
  • Its 3-year average for EBIT is $3.5 million, with a median of -$6.9 million in 2023.
  • As far as peak fluctuations go, CorMedix's EBIT slumped by 56.66% in 2023, and later skyrocketed by 1,661.93% in 2025.
  • Over the past 5 years, CorMedix's EBIT (Quarterly) stood at -$7.8 million in 2021, then decreased by 7.83% to -$8.4 million in 2022, then tumbled by 50.35% to -$10.5 million in 2023, then skyrocketed by 68.59% to $12.9 million in 2024, then spiked by 1,661.93% to $51.3 million in 2025.
  • Its last three reported values are $51.3 million in Q3 2025, $19.5 million for Q2 2025, and $20.1 million during Q1 2025.